Jeune

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024
Research, Investment, Form 10-K, Sale, Form, HSV, Society, KRYS, Immunotherapy, Trial of the century, Genotype, Eye, PI, Krystal, Transgene, European Medicines Agency, Security (finance), Pharmacology, NCT, DEB, Jeune, ID, ODD, AATD, Safety, Survival, Medicaid, IND, Bronchoscopy, IL-12, Gene, MAA, FDA, Patent, Priority review, Cell, Lung, Patient, Medicine, Pharmaceutical industry

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

OpenTable Debuts Annual Top 100 Restaurants List Alongside 2023's Biggest Dining Trends

Retrieved on: 
Wednesday, November 15, 2023
Holiday, Michelin Guide, SAN, Yoy, Restaurant, Alcoholism, Omakase, Diner, Auberge, House, Whisky, City, Girl, Young & Beautiful, Social media, Friends, River Cafe, Energy drink, Saffy's Angel, OpenTable, Negroni, Family, Jeune, Bern's Steak House, Nightclub, Harbor, Bestia, Buccan, Aperol

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- As 2023 comes to a close, bringing holiday and year-end celebrations, OpenTable is helping diners select the perfect venue with the debut of its Top 100 Restaurants in America list for 2023. Featuring an updated methodology using OpenTable diner reviews and new metrics, the list uncovers some of the most in-demand restaurants by OpenTable diners this year.1 

Key Points: 
  • Featuring an updated methodology using OpenTable diner reviews and new metrics, the list uncovers some of the most in-demand restaurants by OpenTable diners this year.1
    Additionally, OpenTable insights from the year (January 1 – September 30) compared to 2022 reveal shifts in diner behaviors and cravings.
  • Solo dining is on the rise: With an increase of 4% YoY, it was the largest increase of any party size.
  • Trends across this year's list include:
    California and Florida see the largest share of restaurants: California features 14 restaurants on the list, including newcomer Saffy's and returning favorites Bavel and Bestia in Los Angeles, along with House of Prime Rib and Kokkari Estiatorio in San Francisco.
  • "This year's Top 100 list features neighborhood gems, hotspots like Bad Roman, MICHELIN-starred venues like Jeune et Jolie, and restaurants new to the list from coast-to-coast," said Soo.

Outdoor Dining Sees 19% Boost in Early June vs. 2022, According to New OpenTable Data

Retrieved on: 
Wednesday, June 28, 2023
Restaurant, Halekulani, Will Rogers Gardens, Longboat Key, Florida, Creativity, Garden, OpenTable, Young & Beautiful, Yoy, Jeune, Nightclub

SAN FRANCISCO, June 28, 2023 /PRNewswire/ -- Summer is here and with it, increased demand for al fresco dining: OpenTable data reveals outdoor dining increased 20% in May and 19% in the first half of June (June 1 – 15), compared to 2022.1

Key Points: 
  • The list spans 20 states with California and Florida again taking top spots, respectively featuring 31 and 17 restaurants.
  • For additional inspiration, use OpenTable's Seating Options filter and select "Outdoor."
  • "Outdoor dining is up 19% YoY for June (1 – 15), a strong start to the season," said Susan Lee, Chief Growth Officer of OpenTable.
  • "With many restaurants elevating outdoor dining spaces for summer and beyond, this list represents dining destinations with incredible outdoor – and culinary – offerings."

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, May 8, 2023
NCT, Netherton syndrome, Cohort, European Medicines Agency, Ministry of Health, Labour and Welfare, Cystic fibrosis, Phase 1, Investment, Patient, Cystic Fibrosis Foundation, TGM1, Ministry of Health (Saudi Arabia), Association for Research in Vision and Ophthalmology, ARVO, Prescription Drug User Fee Act, Pannus, AATD, Rare, Jeune, FDA, IND, Skin, Safety, PIP, RDEB, Eye, Ministry, Financial result, Form, Research, Therapy, KRYS, DEB, MHLW, Clinical trial, Marketing, Annual general meeting, Pharmaceutical industry, Maple syrup, Ophthalmology, PDUFA, Health

Financial results for the quarter ended March 31, 2023:

Key Points: 
  • Financial results for the quarter ended March 31, 2023:
    Cash, cash equivalents, and investments totaled $355.5 million on March 31, 2023.
  • Research and development expenses for the quarter ended March 31, 2023 were $12.3 million, compared to $9.3 million for the quarter ended March 31, 2022.
  • General and administrative expenses for the quarter ended March 31, 2023 were $24.0 million, compared to $15.9 million for the quarter ended March 31, 2022.
  • For additional information on the Company’s financial results for the quarter ended March 31, 2023, please refer to the Form 10-Q filed with the SEC.

Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest

Retrieved on: 
Tuesday, April 18, 2023
KRYS, Cohort, Eye, Ageing, Viper Phase 1, COL3A1, FDA, SVP, Skin, Safety, Pharmaceutical industry, Jeune

PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest.

Key Points: 
  • PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest.
  • Improvement of lateral canthal lines at rest was selected as a target indication for KB301 based upon the Phase 1 safety, efficacy and durability studies, which evaluated KB301 in the lower and upper cheek, including the lateral canthal region.
  • “We plan to initiate a Phase 2 multicenter, double-blind randomized study of KB301 for the improvement of lateral canthal lines at rest following completion of the Phase 1 Cohort 3 study.”
    Currently, there are no FDA-approved injectable aesthetic drugs indicated for lateral canthal lines at rest.
  • Compounding this issue is the fact that lateral canthal lines at rest are one of the most requested aesthetic treatments by adult subjects of all ages.

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

Retrieved on: 
Monday, December 5, 2022
Conference, WOW New & Next, Distraction, ET, HSV, Skin, Krystal, KRYS, Marketing, Ageing, Jeune, Biology, Degenerative disease, Senior, Patient, Vaccine, Ophthalmology

PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8.

Key Points: 
  • PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8.
  • September Riharb, Senior Vice President of Marketing for Jeune, will participate in an aesthetic dermatology panel on December 8 at 11:00 am ET, Distraction or Destruction: What’s New/Next in the Industry. The Jeune and Krystal management team will also attend investor meetings on December 8.
  • Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin.
  • Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases.

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

Retrieved on: 
Thursday, November 17, 2022
Marketing, Skin, Degenerative disease, Food, Human, Krystal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Face, Patient, ET, Ageing, Protein, HSV, SVP, Knee, Cheek, NCT, KRYS, Biology, Safety, Pharmaceutical industry, Vaccine, Jeune

We are pleased to see the sustained durability of effect supporting the clinical benefits afforded by KB301, said September Riharb, SVP of Jeune.

Key Points: 
  • We are pleased to see the sustained durability of effect supporting the clinical benefits afforded by KB301, said September Riharb, SVP of Jeune.
  • Treatment of superficial fine lines has been a challenge for aesthetic physicians, and as one of the first signs of skin aging, fine lines represent a significant unmet need.
  • Previously, the PEARL-1 study evaluated the safety, tolerability, and initial efficacy of intradermal dose-ranging injections of KB301 in adult subjects.
  • Overall, data from the PEARL-1 extension cohort showed up to nine-month durability of effect following administration of high dose KB301.

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

Retrieved on: 
Monday, November 7, 2022
Risk Evaluation and Mitigation Strategies, US FDA, Company, Financial result, Skin, Investment, EMA, Netherton syndrome, Biology, GLOBE, Cystic fibrosis, HSV, FDA, Private Securities Litigation Reform Act, KRYS, Ageing, Priority review, IND, Concha bullosa, BLA, Trial of the century, Marketing, Jeune, Research, U.S. Securities and Exchange Commission, DEB, Degenerative disease, PDUFA, MAA, NASDAQ, Advisory Committee, Form, SEC, Patient, NCT, Pharmaceutical industry, Lithium, Vaccine, EU

PITTSBURGH, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today reported financial results and key operational progress updates for the third quarter ended September 30, 2022.

Key Points: 
  • We are on track to submit a Marketing Authorization Application (MAA) in the fourth quarter of 2022.
  • The Company plans on announcing top line results from the durability trial in the fourth quarter of 2022.
  • Financial results for the quarter ended September30, 2022:
    Cash, cash equivalents, and investments totaled $407.0 million on September30, 2022.
  • For additional information on the Companys financial results for the quarter ended September30, 2022, please refer to the Form 10-Q filed with the SEC.

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

Retrieved on: 
Monday, August 8, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Cell, Private Securities Litigation Reform Act, Trial of the century, GLOBE, Food, Form, SEC, Investment, Jeune, IND, Patient, Marketing, Degenerative disease, CF, Company, Financial result, Twitter, Society, Cohort, Skin, Ageing, NASDAQ, Research, Biology, BLA, Lung, Investor, Knee, LinkedIn, NCT, KRYS, DEB, EMA, Pharmaceutical industry, Vaccine, Lithium

New data on GEM-3 Phase 3 results for B-VEC were presented at the Society for Investigative Dermatology Annual Meeting on May 19, 2022.

Key Points: 
  • New data on GEM-3 Phase 3 results for B-VEC were presented at the Society for Investigative Dermatology Annual Meeting on May 19, 2022.
  • Marketing Authorization Application for B-VEC is anticipated to be filed with the European Medical Agency (EMA) in 2H 2022.
  • Financial results for the quarter ended June 30, 2022:
    Cash, cash equivalents, and investments totaled $438.5 million on June30, 2022.
  • For additional information on the Companys financial results for the quarter ended June30, 2022, please refer to the Form 10-Q filed with the SEC.

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

Retrieved on: 
Monday, May 9, 2022
COL7, Safety, Degenerative disease, Skin, KRYS, SEC, Twitter, NASDAQ, Director, Company, Private Securities Litigation Reform Act, Dermatology, Patient, Clinical trial, Program, Lung, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CF, LinkedIn, Biology, Board of directors, Investment, EMA, IND, U.S. Securities and Exchange Commission, Research, Krystal, DEB, Cohort, NCT, MPH, MBA, Ageing, Financial result, Board, Jeune, N. S. Krishnan, GLOBE, European Medicines Agency, Food, Doctor of Philosophy, Coronavirus Scientific Advisory Board (Turkey), Marketing, American Academy, Nature Medicine, VII, Pharmaceutical industry, Video game, Medical device, Online gambling

New GEM-3 Phase 3 results for B-VEC were presented at the 2022 American Academy of Dermatology Annual Meeting.

Key Points: 
  • New GEM-3 Phase 3 results for B-VEC were presented at the 2022 American Academy of Dermatology Annual Meeting.
  • Financial results for the quarter ended March 31, 2022:
    Cash, cash equivalents, and investments totaled $468.0 million on March 31, 2022.
  • General and administrative expenses for the first quarter ended March 31, 2022 were $15.9 million, compared to $8.2 million for first quarter 2021.
  • For additional information on the Companys financial results for the first quarter ended March 31, 2022, refer to form 10-Q filed with the SEC.